ClearPoint Shares Climb as FDA Announced Clearance To Maestro Brain Model Software
ClearPoint Neuro (NASDAQ: CLPT) announced the U.S. Food and Drug Administration (FDA) 510(k) clearance to its Maestro Brain Model, intended for automatic labeling, visualization, volumetric and shape quantification of segmentable brain structures from a set of MRI images.